Total Funding
53
Total FundingSeries B raised
Growth Score
pts
Heat Score
-7 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
24296
Graphite Bio is a next-generation gene editing company that is driven to apply our breakthrough technology.
Acquired by 
LENZ Therapeutics
- Alethia x Alethia Young: Chief Financial OfficerPast Role: Cantor Fitzgerald, Large Cap Biotech Analyst and Head of Healthcare Research
Phil Gutry: Chief Business Officer, Head of Finance & Investor RelationsPast Role: Regeneron, Executive Director, Business Development
About the Company
Graphite Bio is a clinical-stage, next-generation gene editing company harnessing high efficiency targeted gene integration to develop a new class of therapies to potentially cure a wide range of serious and life-threatening diseases. Graphite Bio is pioneering a precision gene editing approach that could enable a variety of applications to
transform human health through its potential to achieve one of medicine’s most elusive goals: to precisely “find & replace” any gene in the genome. Graphite Bio’s platform allows it to precisely correct mutations, replace entire disease-causing genes with normal genes or insert new genes into predetermined, safe locations.
Women Founded
